Krystal Biotech (NASDAQ:KRYS – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares Krystal Biotech and Monte Rosa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Krystal Biotech | $440.48 million | 21.87 | $204.83 million | $7.98 | 40.78 |
| Monte Rosa Therapeutics | $123.67 million | 7.84 | -$38.63 million | ($1.76) | -6.45 |
Krystal Biotech has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Insider & Institutional Ownership
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Krystal Biotech and Monte Rosa Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Krystal Biotech | 0 | 2 | 10 | 2 | 3.00 |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
Krystal Biotech currently has a consensus target price of $377.20, indicating a potential upside of 15.91%. Monte Rosa Therapeutics has a consensus target price of $26.67, indicating a potential upside of 134.74%. Given Monte Rosa Therapeutics’ higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Krystal Biotech.
Profitability
This table compares Krystal Biotech and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Krystal Biotech | 54.82% | 19.34% | 17.65% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Summary
Krystal Biotech beats Monte Rosa Therapeutics on 13 of the 15 factors compared between the two stocks.
About Krystal Biotech
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
